– GEN’s Editor-in-Chief John Sterling interviews Alan Crane, CEO, Tempo Pharmaceuticals

Previous articleVentana Acquires Spring BioScience for $28.9M
Next articleAradigm and CyDex Combine Expertise to Tackle Asthma and COPD